Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 2 | Vintage Vibes

The No. 1 Stock to Buy on a Panic Sell-Off

The Fed’s hawkish stance to control stubborn inflation has led to a massive sell-off in the stock market this year. Amid this backdrop, we think drug maker Johnson & Johnson (JNJ) could be an ideal buy because of its solid fundamentals and reliable dividends. Read on….

StockNews.com

This Pharmaceutical Stock Is Still a Smart Buy in 2022

Pfizer’s (PFE) co-developed COVID-19 vaccine booster for children, which recently got Emergency Use Authorization from the U.S. FDA, could boost its share price. The stock had witnessed significant attention during the pandemic and could still be worth owning. Let’s discuss this in detail….

StockNews.com

1 Medical Stock That's a Better Buy Than Its Peers

Healthcare giant (MRK) has gained more than 20% in 2022. Moreover, it pays handsome dividends to its shareholders. And its attractive valuations and robust profitability make it a better Buy than its peers. Let's discuss this in detail….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Stocks You Will Want to Own Long Term

The interest rate hikes by central banks around the globe might slow down the global economy. However, staying invested in resilient and dividend-yielding stocks could help garner significant returns in the long run. To that end, Johnson & Johnson (JNJ), Pfizer (PFE), and Ryerson Holding Corporation (RYI) could be ideal…

StockNews.com

The Best Value Stock to Buy for the Long Term

Biopharmaceutical company Bristol-Myers Squibb (BMY) has reported sound financials and possesses a solid upside potential. Given its promising fundamentals, this value stock might be an ideal long-term addition to your portfolio. Keep reading….

StockNews.com

5 Blue Chip Stocks to Help You Beat the Market Slump

Rising concerns over stubbornly-high inflation and the Fed’s commitment to bring it down to its desired level have kept equities under pressure lately. Amid increasing recessionary concerns, investing in blue-chip stocks such as Procter & Gamble (PG), AbbVie (ABBV), Pfizer (PFE), Dow (DOW), and Walgreens Boots Alliance (WBA) could help…

StockNews.com

4 Stocks to Buy With Market-Beating Potential

The stock market has been under pressure amid the high inflation and the Fed’s hawkish tilt. The Fed launched another 75 basis-point rate hike on Wednesday and indicated that it would keep increasing rates to bring down inflation to the target level. Thus, we think fundamentally solid stocks AbbVie (ABBV),…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

1 Stock You'll Wish You Bought Sooner

Amid the highly uncertain market conditions, investors must look for stocks with ample room for growth and better stability. Biopharmaceutical major Pfizer’s (PFE) products remain in demand irrespective of economic cycles. Given its robust financials, discounted valuation, and high profitability, it could be wise to invest in this defensive stock.…

StockNews.com

3 Safe Investments for Seniors to Consider Right Now

August CPI figures indicate that inflation is yet to be controlled, and the Fed might launch another significant interest rate hike next week. As recessionary fears loom over the economy, it might be ideal for seniors to invest in the fundamentally sound stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and…

StockNews.com

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

3 Cannabis Stocks Going up in Flames to Avoid

The wide use of cannabis for recreational activities and its increased medicinal use has helped the market gain traction over the past years. However, with legalization barriers worldwide, this industry is in an odd limbo in which consumption flourishes, but penalties and taxes still prevail. Given the backdrop, it should…

StockNews.com

Should You Follow the Insider Buying in Summit Therapeutics

Shares of the biopharmaceutical company Summit Therapeutics (SMMT) gained over the past few days, driven by significant insider buying. However, as the stock is down more than 55% this year, would it be wise to invest in the stock now? Read on to find out….

StockNews.com

Is Pfizer a Buy Before New Omicron Boosters Roll Out?

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

StockNews.com

Better Buy: Axsome Therapeutics vs. Johnson & Johnson

Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the pharmaceutical sector. But which of these stocks is a better buy now? Read more to find out….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

4 "Strong Buy" Stocks for a Fear-Driven Market

Even though the inflation declined slightly from the 40-year high in July, it stayed elevated. Therefore, the Fed could maintain its hawkish stance on tightening monetary policy, which will drive market volatility. Amid this fear-driven market, we think it could be prudent to invest in fundamentally sound stocks AbbVie (ABBV),…

StockNews.com

3 Large-Cap Healthcare Stocks to Buy for Bigger Gains

Due to the inelastic demand and rising investments, the healthcare sector is witnessing investor confidence amid these uncertain market conditions. Although persistent macroeconomic headwinds might affect stocks in this space, investors could consider buying dividend-paying large-cap stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and UnitedHealth Group (UNH) to…

StockNews.com

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

If You Could Only Buy 1 Stock, This Would Be It

Leading pharma company AbbVie (ABBV) has been witnessing solid business growth, thanks to its lucrative product portfolio and robust financials. And given its record of stable dividend payments, it could be a wise investment now amid the volatile market backdrop. Keep reading….

StockNews.com

Is Buying Pfizer Stock Right Now a Mistake?

StockNews.com

Here's Why Every Investor Might Want to Buy Shares of JNJ

Including dividends, Johnson & Johnson (JNJ) has delivered exceptional returns over the past decade. Given the company’s robust financials, strong dividend-paying history, solid growth prospects, and higher-than-industry profitability, the stock could be an excellent investment amid the current uncertain market conditions. Read on….

StockNews.com

This Health and Wellness Innovator Stock Is up 10% YTD: Should You Buy?

Health and wellness innovator Grove (GRVI) has gained 10% year-to-date. The company has been expanding its portfolio with prominent partnerships and strategic investments. However, given its weak financial positioning, will the stock be able to continue to deliver stable returns? Keep reading….

StockNews.com

Why Investors Are Starting to Turn Bullish on This 1 Stock

Medical cannabis producer Tilray Brands (TLRY) seems to be attracting investors’ attention lately due to its recent product launches. However, its price target has recently been slashed by Piper Sandler (PIPR). Let’s discuss its prospects in detail.

StockNews.com

3 Top Value Stocks Perfect for a Volatile Market

The Fed’s hawkish stance to fight inflation is raising recession concerns. And analysts are becoming increasingly bearish on the near-term prospects. So, we think top-rated value stocks ARC Document (ARC), Assertio (ASRT), and Catalyst Pharmaceuticals (CPRX) could be solid picks to navigate a volatile environment. These stocks are rated Strong…

StockNews.com

Investors Love Bayer, but the Courts Don’t – Buy, Sell, Hold?

Life sciences company Bayer (BAYRY) is currently facing a legal challenge concerning its Roundup. However, farmers have supported the company. On the other hand, despite the market volatility, the stock has been gaining in price. So, is the stock a Buy, Sell, or Hold now? Read on to find out….

1 2 3

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Michael Lavery

14 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.